Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$4.46 +1.0%	$3.40	$2.01 ▼ $5.64	$296.92M	1.52	1.22 million shs	434,694 shs
FENC Adherex Technologies	$8.89 -0.4%	$7.99	$3.96 ▼ $9.30	$245.23M	0.39	80,685 shs	2,790 shs
MGX Metagenomi	$2.14 +1.7%	$1.67	$1.23 ▼ $5.37	$79.81M	-0.38	707,253 shs	182,773 shs
MRNA Moderna	$32.14 +0.2%	$27.62	$23.15 ▼ $126.42	$12.43B	1.84	11.10 million shs	1.34 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	+7.28%	+8.33%	+14.51%	+55.09%	+70.00%
FENC Adherex Technologies	+2.41%	+0.34%	+9.18%	+75.59%	+32.54%
MGX Metagenomi	+0.96%	-9.87%	+45.83%	+38.16%	-60.00%
MRNA Moderna	+1.52%	-2.23%	+23.31%	+29.72%	-74.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.2351 of 5 stars	3.4	0.0	0.0	2.0	0.0	0.6
FENC Adherex Technologies	2.2531 of 5 stars	3.6	1.0	0.0	2.2	3.3	0.0
MGX Metagenomi	2.8878 of 5 stars	3.5	4.0	0.0	2.1	1.7	0.6
MRNA Moderna	4.3464 of 5 stars	4.0	1.0	4.6	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$11.70	162.10% Upside
FENC Adherex Technologies	3.25	Buy	$13.00	46.31% Upside
MGX Metagenomi	3.00	Buy	$13.00	508.90% Upside
MRNA Moderna	2.04	Hold	$46.61	45.04% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, CRDF, and FENC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/13/2025	MRNA Moderna	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Hold
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	436.75	N/A	N/A	$1.86 per share	2.40
FENC Adherex Technologies	$47.54M	5.16	$0.03 per share	269.69	($0.21) per share	-42.31
MGX Metagenomi	$52.29M	1.53	N/A	N/A	$6.28 per share	0.34
MRNA Moderna	$3.24B	3.84	N/A	N/A	$28.33 per share	1.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.11	N/A	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)

Latest MGX, MRNA, CRDF, and FENC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	N/A	N/A	N/A	$0.10 million	N/A
8/13/2025	Q2 2025	MGX Metagenomi	-$0.62	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	FENC Adherex Technologies	-$0.06	N/A	N/A	N/A	$9.52 million	N/A
8/7/2025	Q2 2025	MRNA Moderna	-$2.97	N/A	N/A	N/A	$116.26 million	N/A
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
FENC Adherex Technologies	N/A	5.13	4.97
MGX Metagenomi	N/A	5.85	5.85
MRNA Moderna	N/A	4.22	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
FENC Adherex Technologies	55.51%
MGX Metagenomi	N/A
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
FENC Adherex Technologies	11.76%
MGX Metagenomi	17.80%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
FENC Adherex Technologies	10	27.60 million	24.35 million	Optionable
MGX Metagenomi	236	37.38 million	30.73 million	N/A
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable

MGX, MRNA, CRDF, and FENC Headlines

Recent News About These Companies

Edgestream Partners L.P. Has $2.78 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

July 17 at 5:17 AM | marketbeat.com

William Blair Estimates Moderna's Q2 Earnings (NASDAQ:MRNA)

July 17 at 2:37 AM | americanbankingnews.com

Moderna’s latest approval again reveals FDA rift over COVID vaccines

July 16 at 6:27 PM | biopharmadive.comB

Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)

July 16 at 6:27 PM | msn.com

Eye on Patents: Taking mRNA vaccines beyond COVID-19

July 16 at 6:27 PM | cen.acs.orgC

William Blair Issues Negative Outlook for Moderna Earnings

July 16 at 6:25 AM | marketbeat.com

Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by OVERSEA CHINESE BANKING Corp Ltd

July 16 at 6:00 AM | marketbeat.com

Cwm LLC Buys 28,831 Shares of Moderna, Inc. (NASDAQ:MRNA)

July 16 at 4:54 AM | marketbeat.com

Moderna patent for mRNA vaccine knocked back, for now

July 15 at 12:14 AM | lawyerly.com.auL

Why Moderna (MRNA) Stock Is Falling Today

July 15 at 12:14 AM | msn.com

Moderna: Ready For The Redemption Arc

July 15 at 8:00 AM | seekingalpha.com

Nisa Investment Advisors LLC Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

July 15 at 4:36 AM | marketbeat.com

Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash

July 14 at 9:05 PM | fool.com

Short bets against S&P 500 healthcare stocks climb in June; MRNA tops list again

July 14 at 12:31 PM | msn.com

What to Expect From Moderna's Next Quarterly Earnings Report

July 14 at 7:31 AM | msn.com

Victoria funds mRNA breakthrough research

July 14 at 2:30 AM | manmonthly.com.auM

Bank of New York Mellon Corp Acquires 34,034 Shares of Moderna, Inc. (NASDAQ:MRNA)

July 13, 2025 | marketbeat.com

Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes

July 12, 2025 | finance.yahoo.com

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

July 11, 2025 | zacks.com

U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To Know

July 11, 2025 | msn.com

MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients

July 11, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX, MRNA, CRDF, and FENC Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$4.46 +0.04 (+1.00%)

As of 11:00 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Adherex Technologies NASDAQ:FENC

$8.88 -0.04 (-0.39%)

As of 11:00 AM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Metagenomi NASDAQ:MGX

$2.13 +0.04 (+1.67%)

As of 11:01 AM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna NASDAQ:MRNA

$32.14 +0.08 (+0.24%)

As of 11:01 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time